You have 9 free searches left this month | for more free features.

Myeloid Cell Leukemia 1 Inhibitor

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Acute Myeloid Leukemia, Lymphoma, Mantle-Cell Trial (PEP07)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Lymphoma, Mantle-Cell
  • (no location specified)
Dec 22, 2022

Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation Trial (Biospecimen Collection, Bone

Not yet recruiting
  • Acute Myeloid Leukemia With KMT2A Rearrangement
  • Acute Myeloid Leukemia With NPM1 Mutation
  • Biospecimen Collection
  • +7 more
  • (no location specified)
Jun 1, 2023

Acute Myeloid Leukemia Trial (Azacitidine, Donor lymphocyte infusion, Camrelizumab)

Not yet recruiting
  • Acute Myeloid Leukemia
  • (no location specified)
Mar 15, 2023

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome

Active, not recruiting
  • Acute Lymphoblastic Leukemia
  • +15 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Chicago, Illinois
  • +2 more
Jan 12, 2023

Acute Myeloid Leukemia Trial in Nashville (Biopsy of Bone, Cytarabine, Daunorubicin)

Recruiting
  • Acute Myeloid Leukemia
  • Biospecimen Collection
  • +5 more
  • Buffalo, New York
  • +1 more
Jan 27, 2023

Colorectal Cancer, Hematologic Malignancy, Rectum Cancer Trial in Cleveland (Vactosertib, Fludarabine Phosphate,

Recruiting
  • Colorectal Cancer
  • +11 more
  • Cleveland, Ohio
    University Hospitals Cleveland Medical Center, Case Comprehensiv
Jan 18, 2023

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia Trial in United States (BMF-500)

Not yet recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Los Angeles, California
  • +9 more
Jun 27, 2023

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related

Active, not recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +2 more
  • Tucson, Arizona
  • +2 more
Aug 5, 2022

Acute Myeloid Leukaemia Trial in Worldwide (S 64315 (also referred as MIK665) and azacitidine)

Active, not recruiting
  • Acute Myeloid Leukaemia
  • S 64315 (also referred as MIK665) and azacitidine
  • Houston, Texas
  • +6 more
Dec 16, 2022

Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Trial in United States

Suspended
  • Acute Myeloid Leukemia
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • Los Angeles, California
  • +5 more
Dec 10, 2022

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia Trial in United States (BMF-219)

Recruiting
  • Acute Myeloid Leukemia
  • +12 more
  • Los Angeles, California
  • +6 more
Jun 1, 2022

Acute Myeloid Leukemia (AML) Trial in Birmingham, San Francisco, New York (ZN-d5 ZN-c3, ZN-c3)

Recruiting
  • Acute Myeloid Leukemia (AML)
  • Birmingham, Alabama
  • +2 more
Jan 3, 2023

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (CB-012)

Not yet recruiting
  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia Refractory
  • (no location specified)
Nov 9, 2023

Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia Trial in Boston (Cytokine-Induced Memory-like Natural Killer

Not yet recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Cytokine-Induced Memory-like Natural Killer Cells
  • +2 more
  • Boston, Massachusetts
  • +1 more
Nov 22, 2023

Acute Myeloid Leukemia Trial in Miami (CPX-351, Midostaurin, Busulfan)

Recruiting
  • Acute Myeloid Leukemia
  • Miami, Florida
    Miami Cancer Institute at Baptist Health of South Florida
Jul 27, 2022

Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome Trial in Chicago (Laboratory Biomarker

Completed
  • Acute Myeloid Leukemia
  • +4 more
  • Chicago, Illinois
    University of Chicago Comprehensive Cancer Center
May 12, 2021

Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Decitabine,

Active, not recruiting
  • Acute Myeloid Leukemia
  • +5 more
  • Duarte, California
    City of Hope Medical Center
Jan 4, 2023

Acute Leukemias, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Worldwide (JNJ-75276617)

Recruiting
  • Acute Leukemias
  • +2 more
  • Duarte, California
  • +28 more
Jan 27, 2023

Acute Myeloid Leukemia, MDS, Myeloid Malignancies Trial in Boston (Decitabine, Filgrastim)

Not yet recruiting
  • Acute Myeloid Leukemia
  • +6 more
  • Boston, Massachusetts
  • +1 more
Mar 31, 2023

Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia Trial in

Completed
  • Relapsed or Refractory Haematological Malignancies Including
  • +10 more
  • Aachen, Germany
  • +11 more
Oct 21, 2021

Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Tumor (BPDCN), Relapse Leukemia Trial in Taiyuan (CD123 targeted

Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • CD123 targeted CAR-NK cells
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Aug 28, 2023

AML, Adult, Minimal Residual Disease Trial in Tianjin (CD33/CLL1 dual CAR-NK cell, Cyclophosphamid, Fludarabine)

Not yet recruiting
  • AML, Adult
  • Minimal Residual Disease
  • CD33/CLL1 dual CAR-NK cell
  • +5 more
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Aug 4, 2023

Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Philadelphia (STAT

Active, not recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • STAT Inhibitor OPB-111077
  • +3 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Dec 20, 2022

Myeloid Malignancy, Acute Myeloid Leukemia Trial in Cleveland (Venetoclax, Decitabine)

Not yet recruiting
  • Myeloid Malignancy
  • Acute Myeloid Leukemia
  • Cleveland, Ohio
    University Hospitals Seidman Cancer, Case Comprehensive Cancer C
Nov 8, 2023

Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)

Recruiting
  • Acute Myeloid Leukemia Refractory
  • Acute Myeloid Leukemia, in Relapse
  • anti Tim-3/CD123 CAR-T cell therapy
  • Xuzhou, Jiangsu, China
    Kailin Xu
Nov 4, 2023